Texture Analysis of Breast DCE-MRI Based on Intratumoral Subregions for Predicting HER2 2+Status

被引:16
|
作者
Lu, Hecheng [1 ,2 ]
Yin, Jiandong [2 ]
机构
[1] Northeastern Univ, Sch Med & Bioinformat Engn, Shenyang, Peoples R China
[2] China Med Univ, ShengJing Hosp, Dept Radiol, Shenyang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
breast cancer; receiver operating characteristic; immunohistochemistry; magnetic resonance imaging; gene expression; IN-SITU HYBRIDIZATION; CONTRAST-ENHANCED MRI; NEOADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; MOLECULAR SUBTYPES; FEATURE-SELECTION; CANCER; HETEROGENEITY; EXPRESSION; FEATURES;
D O I
10.3389/fonc.2020.00543
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Breast tumor heterogeneity is related to risk factors that lead to aggressive tumor growth; however, such heterogeneity has not been thoroughly investigated. Purpose: To evaluate the performance of texture features extracted from heterogeneity subregions on subtraction MRI images for identifying human epidermal growth factor receptor 2 (HER2) 2+ status of breast cancers. Materials and Methods: Seventy-six patients with HER2 2+ breast cancer who underwent dynamic contrast-enhanced magnetic resonance imaging were enrolled, including 42 HER2 positive and 34 negative cases confirmed by fluorescence in situ hybridization. The lesion area was delineated semi-automatically on the subtraction MRI images at the second, fourth, and sixth phases (P-1, P-2, and P-3). A regionalization method was used to segment the lesion area into three subregions (rapid, medium, and slow) according to peak arrival time of the contrast agent. We extracted 488 texture features from the whole lesion area and three subregions independently. Wrapper, least absolute shrinkage and selection operator (LASSO), and stepwise methods were used to identify the optimal feature subsets. Univariate analysis was performed as well as support vector machine (SVM) with a leave-one-out-based cross-validation method. The area under the receiver operating characteristic curve (AUC) was calculated to evaluate the performance of the classifiers. Results: In univariate analysis, the variance from medium subregion at P-2 was the best-performing feature for distinguishing HER2 2+ status (AUC = 0.836); for the whole lesion region, the variance at P-2 achieved the best performance (AUC = 0.798). There was no significant difference between the two methods (P = 0.271). In the machine learning with SVM, the best performance (AUC = 0.929) was achieved with LASSO from rapid subregion at P-2; for the whole region, the highest AUC value was 0.847 obtained at P-2 with LASSO. The difference was significant between the two methods (P = 0.021). Conclusion: The texture analysis of heterogeneity subregions based on intratumoral regionalization method showed potential value for recognizing HER2 2+ status in breast cancer.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    CANCERS, 2023, 15 (10)
  • [32] HER2 Intratumoral Heterogeneity in Breast Cancer: Clinicopathologic Characteristics
    Muller, Kristen E.
    Marotti, Jonathan
    Tafe, Laura
    MODERN PATHOLOGY, 2018, 31 : 93 - 93
  • [33] HER2 Intratumoral Heterogeneity in Breast Cancer: Clinicopathologic Characteristics
    Muller, Kristen E.
    Marotti, Jonathan
    Tafe, Laura
    LABORATORY INVESTIGATION, 2018, 98 : 93 - 93
  • [34] Breast cancer HER2 epigenetic intratumoral heterogeneity results from lack of HER2 protein translation
    Nitta, Hiroaki
    Horii, Rie
    Murillo, Adrian
    Portier, Bryce
    Akiyama, Futoshi
    CANCER RESEARCH, 2018, 78 (04)
  • [35] Her2/Neu (HER2) Intratumoral Genetic Heterogeneity in Breast Cancer and Its Concurrent Axillary Metastases
    Astvatsaturyan, K.
    Bose, S.
    LABORATORY INVESTIGATION, 2013, 93 : 28A - 28A
  • [36] Her2/Neu (HER2) Intratumoral Genetic Heterogeneity in Breast Cancer and Its Concurrent Axillary Metastases
    Astvatsaturyan, K.
    Bose, S.
    MODERN PATHOLOGY, 2013, 26 : 28A - 28A
  • [37] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [38] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [39] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Sasagu Kurozumi
    Mary Padilla
    Masafumi Kurosumi
    Hiroshi Matsumoto
    Kenichi Inoue
    Jun Horiguchi
    Izumi Takeyoshi
    Tetsunari Oyama
    Jim Ranger-Moore
    D. Craig Allred
    Eslie Dennis
    Hiroaki Nitta
    Breast Cancer Research and Treatment, 2016, 158 : 99 - 111
  • [40] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Kurozumi, Sasagu
    Padilla, Mary
    Kurosumi, Masafumi
    Matsumoto, Hiroshi
    Inoue, Kenichi
    Horiguchi, Jun
    Takeyoshi, Izumi
    Oyama, Tetsunari
    Ranger-Moore, Jim
    Allred, D. Craig
    Dennis, Eslie
    Nitta, Hiroaki
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 99 - 111